AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02675049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 2µg.kg-1
Description: dexmedetomidine 2µg.kg-1 intranasally 45 min before surgery using a computer-generated random number table.
Study NCT03780010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRC105
Description: Dose-finding study of TRC105 in combination with standard dose bevacizumab and paclitaxel/carboplatin in treatment-naive patients with stage IV non-squamous NSCLC.
Study NCT00966264 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: LNG-IUS
Description: LNG-IUS releasing 25 microg of levonorgestrel
Study NCT00966264 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LNG-IUS
Description: LNG-IUS releasing 25 microg of levonorgestrel
Study NCT00966264 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Hysterectomy
Description: operation
Study NCT00966264 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hysterectomy
Description: operation
Study NCT04396847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorcaserin Oral Tablet
Description: Lorcasering 10mg Oral Tablet (BID)
Study NCT04396847 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Placebo Oral Tablet (BID)
Study NCT02331199 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Amniotic fluid lamellar body count
Description: The LBC (the unit of measurement is number of lamellar bodies counted per microliter of amniotic fluid) will be determined using the platelet channels on the Hematology Flow Cytometer.
Study NCT02331199 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fetal pulmonary artery Doppler
Description: A fetal pulmonary artery Doppler will be performed using color Doppler ultrasound. Doppler flow velocity measurements, including systolic/diastolic ratio, pulsatility index, resistance index, and acceleration-time/ejection-time ratio using spectral Doppler ultrasound.
Study NCT03774290 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBF-680
Description: PBF-680 is an adenosine A1 receptor antagonist
Study NCT03774290 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Oral gelatine capsule
Study NCT04560751 — intervention group
Intervention type: DRUG
Intervention: Lenvatinib
Description: Lenvatinib capsules will be administered orally, once daily (for patients \<60kg, lenvatinib 8mg po; for patients ≥60kg, lenvatinib 12mg po)
Study NCT04560751 — intervention group
Intervention type: PROCEDURE
Intervention: TACE
Description: TACE will be performed as needed.
Study NCT02371772 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Training
Description: Patients were trained to monitor INR and dose warfarin
Study NCT01176461 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MART-1
Description: THIS PEPTIDE REMOVED FROM STUDY ON 1/1/2013. MART-1:26-35(27L) peptide vaccine
Study NCT01176461 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NY-ESO-1
Description: NY-ESO-1 peptide vaccine
Study NCT01176461 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: gp100:209-217(210M)
Description: THIS PEPTIDE REMOVED FROM STUDY ON 1/1/2013. gp100:209-217(210M) peptide vaccine
Study NCT01176461 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: gp100:280-288(288V)
Description: gp100:280-288(288V) peptide vaccine
Study NCT01176461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montanide ISA 51 VG
Description: Administer peptide vaccine emulsions prepared with Montanide® ISA 51 VG by deep subcutaneous injection.
Study NCT01176461 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-936558
Description: BMS-936558 is a fully human monoclonal antibody (HuMAb) against programmed death-1 (PD-1). Level 1: 1 mg/kg cohort; Level 2: 3 mg/kg cohort; Level 3: 10 mg/kg cohort; Level 4: 3 mg/kg prior ipi gr 0/1/2 cohort; Level 5: 3 mg/kg prior ipi gr 3 cohort; Level 6: 3 mg/kg BMS-936558 (no peptide vaccine; human leukocyte antigen \[HLA\] unrestricted)
Study NCT01176461 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: BMS-936558
Description: BMS-936558 is a fully human monoclonal antibody (HuMAb) against programmed death-1 (PD-1). Level 1: 1 mg/kg cohort; Level 2: 3 mg/kg cohort; Level 3: 10 mg/kg cohort; Level 4: 3 mg/kg prior ipi gr 0/1/2 cohort; Level 5: 3 mg/kg prior ipi gr 3 cohort; Level 6: 3 mg/kg BMS-936558 (no peptide vaccine; human leukocyte antigen \[HLA\] unrestricted)
Study NCT02475304 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FP187
Description: FP 187 is given as oral tablets twice daily, 500 mg daily
Study NCT02475304 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00334542 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: simvastatin
Description: 24-28 weeks of simvastatin
Study NCT02332304 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Preterm fetus
Description: A sample of amniotic fluid was taken before the birth of fetus between 26 and 36 6/7 weeks of pregnancy.
Study NCT04669743 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ozone exposure
Description: Exposures will take place at the UCSF Human Exposure Chamber Core Facility. Ozone will be added to the air in the chamber and concentration measured every 30 seconds. Subjects will exercise for two 15-minute intervals of each hour on a cycle ergometer, and will rest for two 15-minute intervals between exercise sessions. The rate of exercise will be individually adjusted to produce a targeted minute ventilation of 15-20 L/min/m2 body surface area. Subjects will be sent home post-exposure and will return to the laboratory on the following day and six days after the exposure for bronchoscopy.
Study NCT03225898 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance Exercise with Blood Flow Restriction
Description: A cuff will be used to restrict blood flow to the extremities.
Study NCT03225898 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High-intensity Resistance Exercise
Description: Participants will follow a conventional resistance exercise regime.
Study NCT02155049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bimatoprost 0.03%
Description: The patients will receive a single daily drop of bimatoprost for six months.
Study NCT03852108 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comfort Care
Description: Face, Hand and body care for 15 to 45 minutes
Study NCT02219698 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Study NCT02219698 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol
Study NCT01947322 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allogenic NK cells infusion
Description: HLA Haploidentical selected NK cell infusion (one injection of 1x107/kg CD3-CD56+ cells) after chemotherapy associating fludarabine, cytosine arabinoside and cyclophosphamide.
Study NCT03747783 — intervention group
Intervention type: PROCEDURE
Intervention: Radical Operation
Description: The surgery treatment selection was based on the American Joint Committee on Cancer stage both of the primary and of the recurrence, as well as on patterns of local spread that were not included in the T classification and on the general condition and preferences of each patient.
Study NCT01597297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB041 (PR Fampridine)
Description: 10 mg twice daily, given orally. Doses of study treatment must be spaced at least 12 hours apart. If a dose of study treatment is delayed or missed, the participant should not dose again until their next scheduled dose. Tablets must be swallowed whole and should be taken without food.
Study NCT01597297 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Twice daily, given orally. Doses of study treatment must be spaced at least 12 hours apart. If a dose of study treatment is delayed or missed, the participant should not dose again until their next scheduled dose. Tablets must be swallowed whole and should be taken without food.
Study NCT00263211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plavix
Study NCT00263211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Study NCT02034162 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mebendazole
Description: Mebendazole will be administered as a single-dose 500 mg chewable tablet. For children 1 year to \<36 months of age, the tablet will be placed in a teaspoon and bottled water will be poured into the remaining volume of the teaspoon. The tablet will then be allowed to absorb all water (absorption time has been observed to take less than 1 minute) to become a soft semi-solid mass without any hard particles. This semi-solid form can then be easily ingested by the child.
Study NCT02034162 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be administered as a single-dose chewable tablet. For children 1 year to \<36 months of age, the tablet will be placed in a teaspoon and bottled water will be poured into the remaining volume of the teaspoon. The tablet will then be allowed to absorb all water (absorption time has been observed to take less than 1 minute) to become a soft semi-solid mass without any hard particles. This semi-solid form can then be easily ingested by the child.
Study NCT01445795 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 200 mg INX-08189 Fasted
Description: 200 mg capsule INX-08189 fasted x7 days
Study NCT01445795 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo QD Fasted
Description: Placebo capsule QD fasted x7 days
Study NCT01445795 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100 mg INX-08189 QD
Description: 100 mg INX-08189 capsule QD x 7 days
Study NCT01445795 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo QD
Description: Placebo capsule Placebo QD dosed with ribavirin x7 days (ribavirin will be dosed in a weight-based fashion as labeled BID)
Study NCT01445795 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100 mg INX-08189 with low-fat meal
Description: INX-08189 100 mg capsule, with low-fat meal QD for seven days
Study NCT01445795 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo with low-fat meal
Description: Placebo capsule administered with a low-fat meal QD for seven days
Study NCT01915901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bismuth subsalicylate (Pepto-Bismol®)
Description: 524 mg bismuth subsalicylate twice a day (BID)
Study NCT01445795 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100 mg INX-08189 BID Fasted
Description: 100 mg INX-08189 BID fasted x7 days
Study NCT01445795 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo BID Fasted
Description: Placebo BID fasted x7 days
Study NCT01445795 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Study NCT02172911 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: INO-3112
Description: 1.1 mL intramuscular (IM) injection of INO-3112 (VGX-3100 + INO-9012) was administered followed immediately by electroporation (EP) with CELLECTRA™-5P on Day 0, Week 4, Week 8, and Week 12.
Study NCT02172911 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CELLECTRA™-5P
Description: CELLECTRA™-5P was used for EP following IM delivery of INO-3112 on Day 0, Week 4, Week 8, and Week 12.
Study NCT00127842 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Etanercept
Description: Administered according to the product monograph by subcutaneous (SC) injection
Study NCT01095159 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TVT-O
Description: Subjects of this group were submitted to surgical treatment of stress urinary incontinence with a transobturator sling TVT-O™ (Gynecare™, USA).
Study NCT01095159 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TVT-S
Description: Subjects of this group were submitted to surgical treatment of stress urinary incontinence with a transobturator mini-sling; TVT-Secur™ (Gynecare™, USA).
Study NCT01240538 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: wild-type reovirus
Description: Given IV
Study NCT01240538 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given PO
Study NCT01240538 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01240538 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT02077205 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Manualised Cognitive Behavioral Therapy
Description: 16 Sessions of Manualised Cognitive Behavioral Therapy in a Routine Care Setting
Study NCT02209844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 44847
Study NCT02209844 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02619214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 30% of oxygen concentration.
Description: 30% oxygen concentration during one hour of general anesthesia.
Study NCT02619214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 60% of oxygen concentration.
Description: 60% oxygen concentration during one hour of general anesthesia.
Study NCT03023722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anetumab ravtansine
Description: Patients will receive anetumab ravtansine IV infusion at a dose of 6.5 mg/kg (recommended Phase II dose) on Day 1 of a 21-day cycle
Study NCT00582725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R-CHOP+GM-CSF
Description: addition of GM-CSF
Study NCT01053481 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin D
Description: Vitamin D supplement
Study NCT01053481 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise program (rebounding on a trampoline)
Description: 40 days at 30 min/d
Study NCT02425540 — intervention group
Intervention type: DEVICE
Intervention: Pelvic MRI
Study NCT02828397 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN2222
Study NCT04154800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986209
Description: Specified Dose on Specified Days
Study NCT04154800 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BMS-986209 Placebo
Description: Specified Dose on Specified Days
Study NCT04154800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Specified Dose on Specified Days
Study NCT04154800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diltiazem
Description: Specified Dose on Specified Days
Study NCT01377298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: 200mg/tablet, 800mg/day PO.
Study NCT01377389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: 10 mg/kg by vein over 90 minutes once every 4 weeks, for 4 weeks.
Study NCT01377389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide
Description: 7.5 mg intramuscular once a month for 8 months
Study NCT01377389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin
Description: 3.6 mg subcutaneous once a month for 8 months
Study NCT01377389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: 80 mg subcutaneous once a month for 8 months
Study NCT01928693 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Besivance 0.6% Ophthalmic Suspension
Description: Drop to be applied in affected eye initially every hour for the first 48 hours then doses will be reduced at each subsequent visit by 50% if patient continues to show a reduction in size of 25% from the previous visit up to every 4 hours. If subject dose has been reduced to every 4 hours at visit 3 and shows an additional reduction size of 25% at visit 4, then they will be reduced to every 6 hours.
Study NCT01928693 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zymaxid 0.5% Ophthalmic Solution
Description: Drop to be applied in affected eye initially every hour for the first 48 hours then doses will be reduced at each subsequent visit by 50% if patient continues to show a reduction in size of 25% from the previous visit up to every 4 hours. If subject dose has been reduced to every 4 hours at visit 3 and shows an additional reduction size of 25% at visit 4, then they will be reduced to every 6 hours.
Study NCT01928693 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vigamox 0.5% Ophthalmic Solution
Description: Drop to be applied in affected eye initially every hour for the first 48 hours then doses will be reduced at each subsequent visit by 50% if patient continues to show a reduction in size of 25% from the previous visit up to every 4 hours. If subject dose has been reduced to every 4 hours at visit 3 and shows an additional reduction size of 25% at visit 4, then they will be reduced to every 6 hours.
Study NCT02882997 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: an interactive computer game
Description: Duck Duck Punch is an interactive computer game designed to elicit repetitive practice of paretic arm movements in stroke patients.
Study NCT02882997 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: standard activities
Description: For community dwelling stroke survivors this is a hard copy, written/illustrated home exercise program for the paretic arm. For inpatient stroke patients this is standard recreational activities organized by the facility during non therapy hours (evenings and weekends).
Study NCT01964846 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Resveratrol, curcumin
Study NCT01964846 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01193998 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as per model probability
Description: Patients randomized to the arm where the clinician is exposed to the model results should be treated as per the model probability (i.e. if the model probability suggests AHF the clinician should treat for AHF).
Study NCT01193998 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment as per usual care
Description: Patients randomized to the arm where the clinician is blinded to the model results will undergo diagnostic tests and receive treatment as per the clinician's judgment and usual care standards.
Study NCT04429282 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibuprofen
Description: Patients were randomly divided into three groups in radio 1:1:1 received respectively IV placebo, ibuprofen 400 mg or ibuprofen 800 mg. The first dose of study drugs was administered intravenously at the time of wound closure and then every 6 hours within 48 hours after the operation.
Study NCT04429282 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03930329 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MBRP group
Description: same as arm description
Study NCT02204020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-azacytidine (5-aza) maintenance therapy after transplant
Description: The planned initial dose of 5-aza is 32mg/m2 (Level 0) administered either subcutaneously or intravenously for days 1 through 5 of a 28-day cycle, which will be initiated between day+30 and day+100 after HCT. Patients who tolerate this dose based on hematologic parameters and with no SAEs for two consecutive cycles will be eligible for a dose escalation to 50mg/m2 (Level +1). Patients who tolerate this dose based on the same criteria as above for two consecutive cycles will be eligible for a dose escalation to 75mg/m² (Level +2). Patients will continue at dose Level +2 for the remainder of the study provided there are no toxicities that require dose reduction. Patients requiring a dose reduction are not eligible for re-escalation.
Study NCT03815370 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental: ABRO™ Binder Arm
Description: ABRO™ is an abdominal device designed to be positioned superficially on the abdominal skin of patients managed with the Open Abdomen strategy. The device is comprised of two rigid plates to stabilize the abdominal muscles thus preventing buckling of these. Another element of this novel device is the circumferential dynamic retainer (CDR). This one is passed behind the patient's back to provide more stability to the muscles in the abdomen keeping them in position to prevent lateral movement of them.
Study NCT03815370 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator: Usual Care
Description: The current approach for temporary coverage of abdomen is called vacuum assisted techniques (VAT). This technique requires the use of vacuum-assisted drainage to remove blood or watery fluid from a wound or operative site.
Study NCT04082351 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nanotechnology structured water ( Magnalife)
Description: Nanotechnology structured water ( Magnalife), is given as dietary supplement to the patients to drink it according to their weight .
Study NCT04082351 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: ordinary water
Description: Ordinary bottled water
Study NCT03602586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epacadostat
Description: Given PO
Study NCT03602586 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV